E

Erytech Pharma SA
PAR:ERYP

Watchlist Manager
Erytech Pharma SA
PAR:ERYP
Watchlist
Price: 0.801 EUR 0.25%
Market Cap: €27.3m

Operating Margin

-408.3%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-408.3%
=
Operating Income
€-27.1m
/
Revenue
€6.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-408.3%
=
Operating Income
€-27.1m
/
Revenue
€6.6m

Peer Comparison

Country Company Market Cap Operating
Margin
FR
Erytech Pharma SA
PAR:ERYP
27.3m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
390.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.8B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 95% of companies in France
Percentile
5th
Based on 2 333 companies
5th percentile
-408.3%
Low
-17 526.7% — 1.3%
Typical Range
1.3% — 11.5%
High
11.5% — 89 700%
Distribution Statistics
France
Min -17 526.7%
30th Percentile 1.3%
Median 6.1%
70th Percentile 11.5%
Max 89 700%

Erytech Pharma SA
Glance View

Market Cap
27.3m EUR
Industry
Biotechnology

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 196 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.

ERYP Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-408.3%
=
Operating Income
€-27.1m
/
Revenue
€6.6m
What is Erytech Pharma SA's current Operating Margin?

The current Operating Margin for Erytech Pharma SA is -408.3%, which is in line with its 3-year median of -408.3%.

How has Operating Margin changed over time?

Over the last 2 years, Erytech Pharma SA’s Operating Margin has increased from -1 851.3% to -408.3%. During this period, it reached a low of -1 851.3% on Dec 1, 2020 and a high of -408.3% on Jan 31, 2023.

Back to Top